MCT4 and CD147 Overexpression Linked to Poor Prognosis in Prostate Cancer
Author Information
Author(s): Pértega-Gomes Nelma, Vizcaíno José R, Miranda-Gonçalves Vera, Pinheiro Céline, Silva Joana, Pereira Helena, Monteiro Pedro, Henrique Rui M, Reis Rui M, Lopes Carlos, Baltazar Fátima
Primary Institution: Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
Hypothesis
The study aims to evaluate the clinico-pathological value of monocarboxylate transporters (MCTs) expression in prostate carcinoma.
Conclusion
MCT4 and CD147 overexpression is associated with poor prognosis markers in prostate cancer.
Supporting Evidence
- MCT2 and MCT4 expression increased significantly in tumor cells compared to normal tissue.
- MCT1 and CD147 expression decreased in prostate tumor cells compared to normal tissue.
- MCT4 and CD147 overexpression correlated with higher PSA levels and advanced tumor stage.
Takeaway
This study found that certain proteins related to cancer metabolism are more active in prostate cancer, which could help doctors understand how aggressive the cancer is.
Methodology
Prostate tissues from 171 patients were analyzed using immunohistochemistry to evaluate protein expression in neoplastic and non-neoplastic tissues.
Potential Biases
Potential biases may arise from the selection of tissue samples and the interpretation of immunohistochemical results.
Limitations
The study may have limitations related to the sample size and the specific patient population analyzed.
Participant Demographics
Patients had a median age of 64 years, with a range from 46 to 74 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website